{"id":"https://genegraph.clinicalgenome.org/r/829dfbd6-fda6-4859-99ec-1bd5155fa47dv1.1","type":"EvidenceStrengthAssertion","dc:description":"The FXN gene is associated with Friedreich ataxia, the most common form of inherited ataxia (Burk 2017, PMID: 28405347; Payne and Wagner 2012, PMID: 22764179). Friedreich ataxia is an autosomal recessive disorder characterized by progressive muscle weakness and ataxia, dysarthria, scoliosis, and cardiomyopathy. Homozygous inheritance of a GAA trinucleotide expansion within intron 1 of FXN accounts for 95% of Friedrich ataxia cases, while 5% of cases are due to compound heterozygous mutations including missense and nonsense mutations in FXN on one allele and the GAA trinucleotide repeat on the second allele (Burk 2017; PMID: 28405347; Delatycki 2000, PMID: 10633128). Friedreich ataxia was first described in 1863, by Nikolaus Friedreich, but it was not until 1996 that Campuzano and colleagues (PMID: 8596916) identified FXN as the causative gene responsible for Friedreich ataxia (Schulz 2013, PMID: 24024236). Many more cases are reported in the literature but the maximum score for genetic evidence (12 pts) has already been reached. Of note, FXN is a gene that is highly conserved from bacteria to mammals, and haplotype analysis has revealed a common ancestor originating from the Franco-Cantabrian ice age refuge (reviewed in Burk 2017, PMID: 28405347). The mechanism for disease is loss of function, as the GAA trinucleotide expansion results in the loss of FXN transcript due to epigenetic regulation. Loss of FXN (frataxin) results in reduced iron homeostasis within mitochondria, and results in mitochondrial dysfunction. This gene-disease association is supported by the function of the gene product, animal models, and rescue experiments. In summary, FXN is definitively associated with Friedreich ataxia. This association has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.\n\nData on the occurrence of hypertrophic cardiomyopathy (HCM) or cardiomyopathy in individuals with Friedreich ataxia was collected by the Hypertrophic Cardiomyopathy Gene Curation Committee (subgroup of the Cardiovascular Working Group). Loss of FXN results in the development of cardiomyopathy in ~92% of patients with Friedreich ataxia, and for 60% of these individualâ€™s heart failure is the primary cause of death within the third to fifth decade of life (Payne and Wagner 2012, PMID: 22764179). The cardiomyopathy involved in Friedreich ataxia includes left ventricular hypertrophy, impaired myocardial perfusion, and arrhythmias. The cardiac hypertrophy observed in Friedreich ataxia was noted to differ from hypertrophic cardiomyopathy, as it is caused by increased proliferation of dysfunctional mitochondria within the cardiomyocytes which can ultimately lead to a dilated left ventricle and reduced ejection fraction (Payne and Wagner 2012, PMID: 22764179; Payne and Perverill 2012; PMID: 22373590).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/829dfbd6-fda6-4859-99ec-1bd5155fa47d","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10008","date":"2021-05-28T20:18:34.686Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10008","date":"2017-12-22T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6180d813-3e1a-4bb4-9fd4-89f30cd1c3d0","type":"EvidenceLine","dc:description":"Increased score due to several lines of evidence repeated by multiple labs.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be4dfb38-c01a-45ee-9cb5-6c8391d17b46","type":"Finding","dc:description":"Northern blot analysis for human tissues shows the highest expression of frataxin in the heart, followed by skeletal muscle, liever, and pancreas. Also mentioned that expression of the transcript was observed in the spinal cord, less expression in the cerebellum and very little in the cerebral cortex (data not shown).\n\nIn PMID: 8841185, Northern blot analysis for human tissues shows high expression of FXN  in pancreas, skeletal muscle, heart. Also shows very good expression in the brain including cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe, and putamen.\n\nIn PMID: 9266741, GFP-tagged FXN was transfected into COS7 cells. The cells were co-immunostianed for a novel mitochondrial marker, CMXRos. Colocalization of FXN-GFP and CMXRos was observed in Cos cells 48-72 hours post transfection.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"FXN Expression in Cardiac and Skeletal Muscle","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/b2f970a1-ca12-4b47-b3b6-0621b705fcd7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/71c80132-cfa8-41d2-a4ad-87d73433ce73","type":"Finding","dc:description":"Proper regulation of iron is necessary for muscular function, with alterations potentially leading to the observed phenotypes","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11030757","rdfs:label":"FXN Iron Homeostasis","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/98460c4a-a7e2-4671-a3fe-937fa0a535a4","type":"EvidenceLine","dc:description":"Does not support this association.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3c60730-e65c-48c5-a721-d7022b337413","type":"Finding","dc:description":"N/A","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8841185","rdfs:label":"FXN Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7567616e-ae5d-43d8-b52e-b00ed995661e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f340ac11-67df-4277-a3a3-2cddad39ffa5","type":"FunctionalAlteration","dc:description":"Knockdown of FXN resulted in a increase in ROS (reactive oxygen species) in the cells compared to scrambled controls. Cell death was also \"modestly, but significantly\" increased in shRNA37 only, not shRNA38, showing a dose dependent effect, and the low levels of FXN are sufficeint to maintin some function. Interstingly knockdown of FXN was associated with reduced capacity for the SH-SY5Y cells to proliferate only in shRNA37. Interstingly these effects were also observed in SH-SY5Y cells that were differentiated into neurons and transduced with shRNAs. \n\nNote that Caspase 3 was show to be activated consistent with cell death in the absence of FXN expression. More experiments were performed to show involvement of p53, but it is unclear how this mechanism may contribute to disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21531789","rdfs:label":"FXN Functional Alteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb66a8bc-1872-4db6-9c7b-a190699b652a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/679aa4a4-0fc0-4757-8bf2-e3ee8a3aed46","type":"Finding","dc:description":" Line Y47 was originally shown to only have one copy of the transgene incorportated, but all subsequent generations showed 2 copies. The YAC-FXN mice were \"indistinguishable\" from controls and were fertile and able to breed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11714098","rdfs:label":"FXN Rescue in Lethal Null Mice","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/97a02499-5bce-43e5-af7b-945acfd9420a","type":"EvidenceLine","dc:description":"This animal model has been published 16 times in literature. Due to the amount of evidence in support of these two mouse models of FXN, I will give max points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9fa3286b-fc74-4aad-a380-396d6a5f09dc","type":"Finding","dc:description":"These mice were further shown to have the Fe-S enzyme deficiency prior to cardiac phenotype development, consistent with FXN function in iron metabolism in mitochondria. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175786","rdfs:label":"FXN Null/KO Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/ec3f674b-1e71-4254-a0f9-f8909becff59_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac7330b4-2f37-4d8d-a199-10c43eb92ac1_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88ea0a05-f010-4118-87ce-6c5228efb4f8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"CAM3","detectionMethod":"SSCP and Southern blot","phenotypes":["obo:HP_0001251","obo:HP_0001315","obo:HP_0001260","obo:HP_0001639","obo:HP_0007340"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ac7330b4-2f37-4d8d-a199-10c43eb92ac1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"FXN, (GAA)n REPEAT EXPANSION, IVS1","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/561195"}},{"id":"https://genegraph.clinicalgenome.org/r/b50590fe-db3e-4787-a658-3535f5374f35","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.460A>T (p.Ile154Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252964"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4cef8bfa-81fc-401f-b948-4caddf8e5ddb_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8793a56c-054f-4ee9-bb8b-9c349022481f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"CAM1","detectionMethod":"SSCP and Southern blot/ RED shows the inheritance of the L106X mutation paternally, and the GAA expansion maternally","phenotypes":["obo:HP_0001260","obo:HP_0007340","obo:HP_0001639","obo:HP_0001251","obo:HP_0001315"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4cef8bfa-81fc-401f-b948-4caddf8e5ddb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","allele":[{"id":"https://genegraph.clinicalgenome.org/r/e4338b13-26c6-450f-9a03-43e4822ae1d5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.317T>G (p.Leu106Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252961"}},{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5a4c82f1-45de-4f42-a660-617abb58d4c3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95dba5e4-d35c-4b55-8056-10d9be36c727","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"CAM5","detectionMethod":"SSCP and Southern blot","phenotypes":["obo:HP_0001260","obo:HP_0001315","obo:HP_0001639","obo:HP_0007340","obo:HP_0001251"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5a4c82f1-45de-4f42-a660-617abb58d4c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/80fc7921-82f3-4ca6-96a8-35d58e09af34_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF. Additionally, the other allele leads to a frameshift and premature termination. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/690ed90d-c4b7-4274-8dab-c53e0540353e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","rdfs:label":"P785","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":10,"detectionMethod":"Blood samples and biological specimens were obtained from the patients and their healthy relatives. Genomic DNA was isolated, with PCR amplification of Exons 1-5A and 5B of FXN being performed followed by direct sequencing.","phenotypeFreeText":"Wheelchair-bound 25 yrs","phenotypes":["obo:HP_0001260","obo:HP_0002650","obo:HP_0002522","obo:HP_0001639","obo:HP_0002495","obo:HP_0000763","obo:HP_0007210","obo:HP_0007340","obo:HP_0007240","obo:HP_0002070","obo:HP_0001265","obo:HP_0007256","obo:HP_0003115"],"previousTesting":true,"previousTestingDescription":"21.8% fratraxin protein levels","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/80fc7921-82f3-4ca6-96a8-35d58e09af34_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","allele":[{"id":"https://genegraph.clinicalgenome.org/r/995e7eac-472e-4b39-a07f-60fbbe4e94db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.99del (p.Ala34ProfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA193369008"}},{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/da7a2325-6600-4a61-b548-52b0b4cc30c6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF. Additionally, the other allele leads to a premature termination. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ad40a81-330a-4122-b47f-034beff56eaf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","rdfs:label":"P585","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"detectionMethod":"Blood samples and biological specimens were obtained from the patients and their healthy relatives. Genomic DNA was isolated, with PCR amplification of Exons 1-5A and 5B of FXN being performed followed by direct sequencing.","phenotypeFreeText":"Wheelchair-bound 22 yrs","phenotypes":["obo:HP_0001152","obo:HP_0002522","obo:HP_0002070","obo:HP_0002078","obo:HP_0002650","obo:HP_0000763","obo:HP_0007256","obo:HP_0002495","obo:HP_0007240","obo:HP_0007340","obo:HP_0003115","obo:HP_0001265","obo:HP_0001260","obo:HP_0007210","obo:HP_0001639","obo:HP_0000639"],"previousTesting":true,"previousTestingDescription":"19.4% fratraxin protein levels","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/da7a2325-6600-4a61-b548-52b0b4cc30c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},{"id":"https://genegraph.clinicalgenome.org/r/85fe0e6b-b8b5-4559-951b-e7eecde16834","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.354C>G (p.Tyr118Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA193385376"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/79bb19b4-96f0-41a7-8921-7196252003a8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF. Additionally, the other allele leads to a frameshift and premature termination. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3449e37d-997a-4665-8a8f-a19681501c70","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","rdfs:label":"P550","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":8,"detectionMethod":"Blood samples and biological specimens were obtained from the patients and their healthy relatives. Genomic DNA was isolated, with PCR amplification of Exons 1-5A and 5B of FXN being performed followed by direct sequencing.","phenotypes":["obo:HP_0007256","obo:HP_0002070","obo:HP_0002650","obo:HP_0001760","obo:HP_0000639","obo:HP_0001260","obo:HP_0007240","obo:HP_0007340","obo:HP_0001265","obo:HP_0007210","obo:HP_0002522","obo:HP_0000763","obo:HP_0003115","obo:HP_0002078","obo:HP_0002495"],"previousTesting":true,"previousTestingDescription":"30.9% fratraxin protein levels","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/79bb19b4-96f0-41a7-8921-7196252003a8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},{"id":"https://genegraph.clinicalgenome.org/r/821f4fd2-5202-4c7f-8fe4-06b18e994e23","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.157del (p.Arg53AlafsTer23)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575483"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a683d0c4-f997-4c32-81b8-89cfce992758_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF. Additionally, the other allele leads to a frameshift and premature termination. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aac97de5-0c56-41b1-8aac-4ccfebe1b0f3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","rdfs:label":"P840","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":11,"detectionMethod":"Blood samples and biological specimens were obtained from the patients and their healthy relatives. Genomic DNA was isolated, with PCR amplification of Exons 1-5A and 5B of FXN being performed followed by direct sequencing.","phenotypeFreeText":"Wheelchair-bound 25 yrs","phenotypes":["obo:HP_0001152","obo:HP_0000763","obo:HP_0002522","obo:HP_0003115","obo:HP_0007340","obo:HP_0001265","obo:HP_0000639","obo:HP_0002650","obo:HP_0007210","obo:HP_0007256","obo:HP_0002070","obo:HP_0001260","obo:HP_0002078","obo:HP_0007240","obo:HP_0002495","obo:HP_0002015"],"previousTesting":true,"previousTestingDescription":"19.9% fratraxin protein levels","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a683d0c4-f997-4c32-81b8-89cfce992758_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17703324","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},{"id":"https://genegraph.clinicalgenome.org/r/87253855-93cc-405a-91ea-0fb4924473d4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000144.5(FXN):c.101del (p.Pro35HisfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA193369020"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/78940627-5ec3-4fc9-ba9a-81b9415bc39b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The GAA trinucleotide expansion was shown to pertub transcription, supporting one varint LOF.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/421c8f1e-07c1-412a-bcdb-2adc1a725f03","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"CAM4","detectionMethod":"Southern Blot, RE digest","phenotypes":["obo:HP_0007340","obo:HP_0001260","obo:HP_0001639","obo:HP_0001251","obo:HP_0001315"],"previousTesting":true,"previousTestingDescription":"Fig 3- Saudi family","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/78940627-5ec3-4fc9-ba9a-81b9415bc39b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4c6de8c8-f99c-40f2-8923-c64ee071e440_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Splice acceptor site mutation, but no variant evidence to suggest it is LOF. However the GAA repeat is shown to inhibit transcription of FXN, so at least one demonstrated LOF.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5b0ac313-fd9d-4c21-b916-1961a70244fc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","rdfs:label":"CAM2","detectionMethod":"SSCP","phenotypes":["obo:HP_0007340","obo:HP_0001639","obo:HP_0001260","obo:HP_0001251","obo:HP_0001315"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4c6de8c8-f99c-40f2-8923-c64ee071e440_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8596916","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9b7de313-1482-4564-8d55-f26d3761f365"},{"id":"https://genegraph.clinicalgenome.org/r/e4338b13-26c6-450f-9a03-43e4822ae1d5"}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":2841,"specifiedBy":"GeneValidityCriteria5","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/jX1EzYFPTps","type":"GeneValidityProposition","disease":"obo:MONDO_0100339","gene":"hgnc:3951","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ec3f674b-1e71-4254-a0f9-f8909becff59-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}